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PURPOSE: To determine if fluconazole is effec- 
tive treatment for hepatosplenic candidiasis that 
has not resolved with amphotericin B and flucy- 
tosine treatment. 
PATIENTS AND METHODS: Six patients (ages 3 to 
44) with acute leukemia and hepatosplenic can- 
didiasis who did not respond to prior antifungal 
therapy were treated with fluconazole. 
RESULTS: All six patients had fever and three 
had nausea and vomiting, computed tomograph- 
ic (CT) scan showed lucencies in the liver in six, 
lucencies in the spleen in five, and lucencies in 
the kidneys in three. Prior therapy with 1.6 to 4 
g of amphotericin B in the five adults and 526 
mg of amphotericin B in the child (with the ad- 
dition of flucytosine in four) failed to improve 
clinical symptoms or lucencies in the liver, 
spleen, and kidneys seen on CT scan. Flucona- 
zole was given at a dose of 266 to 466 mg daily 
(70 to 160 mg in the child) for 2 to 14 months. All 
patients had resolution of fever and other symp- 
toms in 2 to 8 weeks. Improvement of the lesions 
notedonCTscanwasseenin4to8weeksinall 
patients. Total resolution of lesions noted on CT 
scan occurred by 4 weeks in two patients, but 
took 4 to 5 months for three patients and 13 
months for one patient. Three patients had re- 
lapse of their acute leukemia and two died, pre- 
sumably cured of their candidiasis. Two patients 
underwent successful bone marrow transplanta- 
tion without relapse of their candidiasis. 
CONCLUSION: l?hWOIiaZole appears to be useful 
in the treatment of hepatosplenic candidiasis 
that has not resolved with amphotericin B and 
flucytosine therapy. 
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A distinct clinical syndrome, hepatosplenic can- didiasis, appears to be increasing in immuno- 
compromised hosts [l-5]. This form of candidiasis, 
characterized by focal persistent microabscesses in 
liver, spleen, and sometimes in kidneys, usually oc- 
curs in patients with acute leukemia who have re- 
covered from neutropenia. These patients present 
with fever, abdominal pain, anorexia, nausea, and 
vomiting [3-51. This form of candidiasis has been 
very difficult to treat, many times persisting after 
months of therapy [5]. 
We report on six patients with this syndrome who 
continued to be ill despite treatment with ampho- 
tericin B. All six were treated with fluconaxole and 
had eradication of their Candida infection. 
PATIENTS AND METHODS 
Six patients with culture- and/or histopatholog- 
ic-documented hepatosplenic candidiasis were 
treated from January 1989 to July 1990. All had 
been treated with amphotericin B, four had re- 
ceived flucytosine, and two had received ketocona- 
zole prior to use of fluconaxole. Failure of prior anti- 
fungal therapy was defined as persistent fever, 
persistent or worsening liver lesions on computed 
tomographic (CT) scan of the abdomen, and per- 
sisting or progressing clinical symptoms. Informed 
consent was obtained from all patients or parents in 
the case of the child. Clinical symptoms and labora- 
tory parameters were followed every 2 to 4 weeks for 
the duration of therapy with fluconazole. 
Treatment with fluconazole was begun at a dose 
of 200 mg orally daily and increased to 400 mg orally 
daily after several weeks in all of the adults; the 
child received 70 mg intravenously daily and then 
was switched to lOO-mg tablets after 3 months. The 
drug was administered intravenously in two adults 
when nausea and vomiting precluded oral intake. 




The ages of the six patients ranged from 3 to 44 
years. All had acute leukemia, which was in remis- 
sion when hepatosplenic candidiasis was diagnosed. 
All six had fever as the primary symptom of their 
illness, three had nausea and vomiting, two had 
hepatomegaly, and one had right upper quadrant 
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TABLE I 
Cllnical Characteristics and Response to Prior Antifungal Therapy 
Patient 
Number Age/Sex Sites CT Scan Pathology Culture 
Prior Treatment (duration) 
AmB* 5FC Keto 
I 1 32/M LS LS (+) L(+) L(+) 1.5 months - 2 weeks 
I 
(1.6g) 
2 44/F LK LK (+) L (-) L C-J 6 months - - 
(2.9 g) 
3 36/F L&K LSJ (+I L(+) L C-1 3 months 3months - 
(3.5 g) 
4 3/F LSJ L,S,K (+) L (+) L(+) 2 months 2 months - 
(526 mg) 
5 44/M LS LS (+) L (+I L(-1 3 months 3 months 1 month 
6 18/M LS LS (+I s (+) s C-1 Z.~r%nths 2.5 months - 
\L.Y gl (2 9 )
I 
AmB = amphotericin B; 5-FC = flucytosine; Keto = ketoconazole: L = liver; S = spleen; K = kidneys. 
* Number in parentheses = total dose of amphotericin B. 
TABLE II 
Response to Fluconazole Treatment 
I 
Patient Fluconazole Therapy 
Numbar Bose (mg) Duration 
Response to Therapy 












6 200 2 weeks 











Fever resolved-Week 3; nausea, 
vomiting worse, fever returned 
(due to leukemia) 
Fever resolved-Week 4; nausea, 
vomiting resolved-Week 6 
Fever resolved-Week 6; nausea, 
vomiting resolved-Week 8 
Fever resolved-Week 8 
Fever resolved-Week 4 
Fever intermittent prior to 
fluconazole; felt better by Week 
2 
Normal-Week 4 
L improved, K worse- 
Week 6; L normal, K 











Candidiasis resolving; leukemia 
relapsed and patient died 
Candidiasis resolved; BM TX 5 
months after therapy 
stopped-no relapse of 
candidiasis 
Candidiasis resolved; leukemia 
relapsed and patient died 
Candidiasis resolved; leukemia in 
remission 
Candidiasis resolved; leukemia 
relapsed after fluconazole 
stopped 
Candidiasis resolved; BM TX in 
Week 10 of therapy-no relapse 
of candidiasis 
I 
L = liver: K = kidneys; BM TX = bone marrow transplantation. 
* Intravenous fluconazole was given at the dose indicated for 10 days (Patient l), 8 days (Patlent 2) and 3 months (Patient 4). 
bain. The sites of involvement were liver (six), candidemia at any point during their treatment for 
spleen (five), and kidneys (three) (Table I). acute leukemia. 
Diagnostic Studies 
Four of the six patients had the diagnosis estab- 
lished by liver biopsy, which showed abscesses with 
yeast and hyphal forms characteristic of Candida, 
and one patient had a splenectomy, which revealed 
multiple abscesses with Candida. Only two of the 
five tissue specimens yielded Candida albicans 
when cultured. The sixth patient had a percutane- 
ous liver biopsy, which did not show fungi, but she 
had already received 2 months of amphotericin B 
therapy. However, she previously had Candida 
tropic&is grown from blood and skin lesions 3 
months prior to the liver biopsy, characteristic 
lucencies in the liver and kidney on a CT scan of the 
abdomen, and persistent fever, nausea, and vomit- 
ing. None of the other patients had documented 
CT scans of the abdomen showed characteristic 
multiple lucencies in the liver in all patients, with 
involvement of spleen and kidneys noted less fre- 
quently (Table I). At the time of diagnosis of hepa- 
tosplenic candidiasis, white blood cell counts varied 
widely (1,80O/~L to 35,OOO/~L), but were low only in 
the S-year-old girl. The alkaline phosphatase level 
was abnormal in all but one patient (114 U/L to 701 
U/L). The bilirubin level was elevated in only one 
patient, and the alanine aminotransferase and as- 
partate aminotransferase values were within nor- 
mal limits in all six. 
Prior Antifungal Therapy 
All six patients had been treated with amphoteri- 
tin B for as long as 1.5 to 6 months, and four re- 
ceived flucytosine concomitantly (Table I). The to- 
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tal dose of amphotericin B received by the five 
adults was 1.6 to 4 g (mean = 2.9 g), and the 3-year- 
old patient received a total of 44 mg/kg. Two pa- 
tients received ketoconaxole, one for 2 weeks and 
one for 4 weeks. 
Fever persisted in all the patients throughout 
their course of amphotericin B therapy; Patient 6 
had only intermittent low-grade fevers, but the oth- 
er five patients had daily spiking elevations of tem- 
perature. Five patients had persistently elevated 
alkaline phosphatase values. CT scanning showed 
persistence of lucencies in the liver in two patients 
and increased number and size of lesions in four 
patients. Laparotomy after 4 months of therapy 
with amphotericin B/flucytosine and then ketocon- 
axole in Patient 5 showed multiple liver abscesses 
with fungi noted on histopathologic examination. 
Response to Fluconazole Therapy 
All six patients responded to treatment with flu- 
conaxole (Table II). Symptoms of fever, nausea and 
vomiting, and abdominal pain resolved within 3 to 8 
weeks. Patient 1 had initial resolution of fever, then 
recurrence in the fourth week, but this was most 
likely due to a relapse of his acute leukemia, which 
progressed to cause his death in Week 9 of therapy. 
The level of alkaline phosphatase was not useful 
in all patients as a measure of response to therapy. 
In two patients, decreasing alkaline phosphatase 
values correlated with clinical and CT scan im- 
provement. However, in two others the values fell to 
normal, only to increase again, probably related to a 
relapse of leukemia. The child had persistently ele- 
vated levels, presumably due to bone growth. 
The timing of repeated CT scans was decided by 
the patient’s primary physician so that the actual 
time of resolution of lesions was not established in 
most patients. In two patients, the CT scan was 
normal by Week 4 of therapy; in four patients, im- 
provement in the lesions in the liver was noted by 
Weeks 5 to 8 of therapy (Figure 1). Two of these 
four patients showed complete resolution of lucen- 
ties on CT scan after 5 months of therapy. The 
response of Patient 5 was difficult to evaluate be- 
cause scans were done so infrequently; 13 months 
after fluconaxole treatment was begun, his CT scan 
was normal. Patient 2 had resolution of lesions in 
the liver by Week 8, but worsening kidney lesions 
during this time, with final resolution by Week 14. 
Three patients had relapse of their acute leuke- 
mia. Patient 1 died of leukemia, and his candidiasis 
appeared to be resolved but no necropsy was per- 
formed. Patient 3 tolerated reinduction chemo- 
therapy, had resolution of candidiasis, but then had 
another relapse of leukemia and died. Patient 5 had 
gradual resolution of his candidiasis (by Week 8, 
symptoms resolved and a CT scan improved, with a 
FLUCONAZOLE FOR HEPATOSPLENIC CANDIDIASIS / KAUFFMAN ET AL 
Figure 1. CT scans of the abdomen in Patient 6. Top, multiple 
lucencies in the liver after amphotericin B and flucytosine 
had been given for 2 months (December 27, 1989); middle, 
after 5 days of fluconazole therapy, there is no change and 
perhaps worsening of the liver lesions (January 17, 1990); 
bottom, after 1 month of fluconazole therapy, lesions have 
resolved completely (February 12, 1990). 
normal CT scan documented by Month 13 of thera- 
py with fluconazole), and then had a relapse of leu- 
kemia after fluconazole administration had been 
stopped. 
Two patients underwent successful bone marrow 
transplantation without relapse of their candidia- 
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sis-one in Month 3 of therapy and one 5 months 
after therapy had been stopped. Patient 4 had reso- 
lution of her candidiasis during maintenance che- 
motherapy and has done well with no relapse of her 
leukemia. 
The length of therapy was determined by several 
factors, including the clinical response to therapy, 
the status of the leukemia, and patient decisions. 
For example, the two patients who received less 
than 3 months of therapy did so because one had 
relapse of leukemia, was not treated with a further 
course of chemotherapy, and died soon after (Pa- 
tient l), and the other patient elected to stop thera- 
py because she believed that fluconaxole had caused 
her to have a seizure (Patient 2). Other patients 
were treated until both clinical and CT scan resolu- 
tion had occurred, and two were treated for over a 
year because they were doing well and their physi- 
cians believed it best to continue therapy to be cer- 
tain of cure of their infection. 
No side effects of fluconaxole therapy were noted. 
It was not believed that the seizure experienced by 
Patient 2 was related to fluconaxole, especially 
since a lesion was noted on magnetic resonance im- 
aging scan in an area corresponding to her focal 
seizure activity. 
COMMENTS 
Hepatosplenic candidiasis has become a major 
problem in the population of patients with acute 
leukemia who have undergone successful induction 
chemotherapy and whose disease is in remission. 
The development of abdominal complaints and fe- 
ver may herald the development of this syndrome 
[3-51. CT scan or ultrasound examination will usu- 
ally show the characteristic lesions in liver, spleen, 
and kidneys [6], and biopsy will show yeast and 
hyphal forms characteristic of Can&da in areas 
with varying amounts of necrosis and granuloma- 
tous inflammation. Interestingly, cultures taken 
from involved tissues are often negative [5]. Despite 
negative cultures, symptoms persist and the patient 
will not improve without antifungal therapy. Given 
the fact that many of these patients will require 
further markedly immunosuppressive procedures, 
such as bone marrow transplantation, to definitive- 
ly treat their leukemia, eradication of visceral foci 
of Candida is essential. 
An as yet unexplained aspect of this syndrome is 
the poor response to therapy with antifungal drugs 
[4,5,7,8]. The five adults described in this report 
had received from 1.6 g to 4.0 g of amphotericin B 
with minimal clinical or radiographic improvement. 
It is possible, however, that higher daily doses or a 
longer course of therapy with amphotericin B might 
have led to resolution of infection in these patients. 
Thaler et al [5] describe a patient who required 
amphotericin B therapy for 14 months before final- 
ly achieving cure. There is suggestive clinical and 
experimental animal evidence that the combination 
of amphotericin B and flucytosine may be more 
effective than amphotericin B alone [5,9]; four of 
our patients had received both drugs and still did 
not respond. The experience with ketoconazole, al- 
though limited, has not been encouraging [4,5]. 
In contrast, the experience with liposomal am- 
photericin B has been very encouraging. Lopez- 
Berestein et al [7] found that 13 of 17 patients with 
hepatosplenic candidiasis responded to liposomal 
amphotericin B therapy. Standard antifungal ther- 
apy had failed in all of these patients. The liposomal 
preparation allows very large doses of amphotericin 
B to be given with minimal or no toxicity, and high 
concentrations of drug are achieved in organs of the 
reticuloendothelial system, such as the liver and 
spleen [lO,ll]. A similar excellent response to ther- 
apy with a different liposomal amphotericin B 
preparation has been noted by Sculier et al [12]. 
However, only a limited amount of liposomal am- 
photericin B is available for experimental clinical 
use at this time. A similar preparation, amphoteri- 
tin B-lipid complex, is currently undergoing limited 
trials in the treatment of fungal infections and may 
prove to be useful. 
All of our patients responded to fluconaxole after 
not responding to other antifungal therapy. In sev- 
eral, the response was dramatic with prompt resolu- 
tion of clinical symptoms; in others, response oc- 
curred very slowly after several months of therapy. 
Resolution of lesions on CT scan was slower than 
clinical improvement, and the alkaline phosphatase 
level was not as helpful for following the response to 
therapy as the clinical and radiologic parameters. 
No relapses of candidiasis occurred, even though 
several patients experienced relapse of leukemia 
and were given reinduction chemotherapy. The ap- 
propriate total duration of therapy is not clear. 
Whether the long course of therapy (more than 1 
year in two patients) prevented relapse of candidia- 
sis is not clear. It seems prudent to continue to treat 
throughout the time of maximum immunosuppres- 
sion, such as occurs with intensive chemotherapy 
and bone marrow transplantation. Interestingly, 
Patient 2 stopped taking the drug herself at a time 
when her physicians believed she may still have had 
active candidiasis. Five months later, she under- 
went bone marrow transplantation and did not 
have a recurrence of candidiasis. 
Although this report concerns only a small num- 
ber of patients, the response to fluconazole therapy 
was encouraging, and similar to that reported by 
others [8,13]. Why fluconazole should be effective 
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when amphotericin B was not is not clear. It is pos- 
sible that prior therapy with amphotericin B was 
essential to resolution of hepatosplenic candidiasis 
in these patients. Perhaps persistence of amphoter- 
icin B in the liver well after therapy was stopped 
contributed to the eventual resolution of infection 
[14]. Whether fluconazole should be used as pri- 
mary therapy for this disease has not been answered 
by this study and would require a multicenter 
randomized trial comparing amphotericin B with 
fluconazole. 
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